ANI Pharma posts record Q1 revenue $197.1M (+43%); raises FY2025 guidance

ANI PHARMACEUTICALS INC

2025-Q1 EPS reported $0.69 revenue$197,122,000

Record Q1 net revenue $197.1M (+43.4% YoY); Rare Disease $69.0M (Cortrophin Gel $52.9M, +43.1%).
Record adjusted non-GAAP EBITDA $50.7M (+34.9%); adjusted diluted EPS $1.70, up from $1.21 YoY.
Generics revenue $98.7M (+40.5%) driven by new launches including first-to-market prucalopride.
Raised 2025 guidance: net revenue $768M-$793M, EBITDA $195M-$205M, adjusted EPS $6.27-$6.62.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.